Group 1 - The core viewpoint of the news is that Jinfang Pharmaceutical-B (02595) has successfully conducted an oversubscribed IPO, raising significant capital for its clinical development projects [1][2] - The company recorded a total subscription of HKD 349.85 billion, with the public offering portion being oversubscribed by 2,210 times [1] - Jinfang Pharmaceutical plans to issue 77.6 million H-shares at a price of HKD 20.39 per share, aiming to raise HKD 1.58 billion [1] Group 2 - The company focuses on developing new treatment solutions for oncology, autoimmune, and inflammatory diseases, with a product pipeline that includes eight candidate products [1][2] - Two core products, GFH925 and GFH375, are in clinical development, with GFH925 already commercialized in China for treating advanced non-small cell lung cancer (NSCLC) [1][2] - The net proceeds from the IPO will be allocated as follows: approximately 33% for the clinical development of GFH925, 38% for GFH375, 19% for other candidate products, and 10% for general corporate purposes [2]
劲方医药-B孖展认购金额逾3498亿港元 超购2210倍